TLDR Federal Reserve held interest rates at 3.5%-3.75% Wednesday, pausing cuts for first time since July US dollar fell to four-year lows following its worst annualTLDR Federal Reserve held interest rates at 3.5%-3.75% Wednesday, pausing cuts for first time since July US dollar fell to four-year lows following its worst annual

Fed Rate Decision January 2026: No Change as Inflation Persists

2026/01/29 20:41
3 min read

TLDR

  • Federal Reserve held interest rates at 3.5%-3.75% Wednesday, pausing cuts for first time since July
  • US dollar fell to four-year lows following its worst annual showing since 2017
  • Stephen Miran and Chris Waller dissented, preferring a 25-basis-point rate reduction
  • Bitcoin traded near $89,500 after the decision while gold climbed to $5,300 per ounce
  • Probability of March rate cut stands at 16%, with April odds at 30%

The Federal Reserve kept interest rates steady on Wednesday at 3.5% to 3.75%. The Federal Open Market Committee voted to pause rate changes for the first time since July.

The decision matched market predictions. Traders had priced in a 99% probability of no rate movement before the meeting.

Fed officials cited ongoing inflation concerns. The policy statement highlighted low job gains and stabilizing unemployment. The central bank described inflation as “somewhat elevated.”

Two committee members broke from the majority. Stephen Miran, recently appointed by President Trump, voted for a quarter-point cut. Chris Waller also favored reducing rates by 25 basis points.

Bitcoin remained close to $89,500 following the announcement. Stock markets showed minimal reaction. Gold prices pushed higher, nearing record levels at $5,300 per ounce.

Currency Markets Show Weakness

The US dollar continued its downward trend this week. The Bloomberg Spot Dollar Index dropped to its lowest point in four years. The currency recorded its worst yearly performance since 2017.

President Trump has repeatedly called for lower interest rates. When asked about the dollar’s decline, he responded that “the value of the dollar is great.”

Market observers see strategy in the currency movement. The Kobeissi Letter called it evidence that “President Trump is willing to tolerate a weaker Dollar to push rates lower and boost US exports.”

David Ingles from Bloomberg TV APAC shared this view. He noted Trump may be “cutting rates on the Fed’s behalf by letting the dollar slide.”

Impact on Digital Assets

Cryptocurrency prices have fluctuated around Fed decisions. Traders are divided on how future policy changes will affect digital asset valuations.

Analysts identify a negative correlation between Bitcoin and the US Dollar Index. Stronger dollar values typically pressure cryptocurrencies lower. A declining dollar often supports risk assets.

Hong Kong-based platform OSL has documented this inverse relationship. Their research suggests dollar strength reflects shifts in investor risk appetite.

Julien Bittel from Global Macro Investor described a strong dollar as harmful to risk assets. He warned it can significantly tighten global financial conditions.

Rate cut expectations have changed substantially. November prediction markets showed 40% odds for a January cut. Those probabilities collapsed to zero by meeting time.

Future rate cut chances remain low. CME FedWatch shows 16% probability for a March reduction. The odds improve slightly to 30% for April.

Nick Ruck from LVRG Research analyzed the decision’s market effects. He explained the rate hold stems from inflation worries and economic stabilization. He warned this could trigger short-term volatility in cryptocurrency markets.

Jerome Powell held his press conference at 2:30 pm ET after the meeting. Market participants watched closely for signals about the Fed’s future approach.

The post Fed Rate Decision January 2026: No Change as Inflation Persists appeared first on Blockonomi.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26